Shuangyou Liu

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Systemic evaluation for extramedullary disease and treatment outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Systemic evaluation for extramedullary disease and treatment outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Journal: Leukemia research

Published: February 01, 2026

CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies.

CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies.

Journal: American journal of clinical pathology

Published: September 02, 2024

Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation.

Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation.

Journal: Haematologica

Published: August 28, 2024

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.

Journal: Blood advances

Published: July 10, 2024

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.

Journal: BMC cancer

Published: January 23, 2022

CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis.

CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis.

Journal: Cancer reports (Hoboken, N.J.)

Published: October 05, 2021

Quick identification of target antigens by tissue flow cytometry for CAR-T therapy in B-cell malignancies.

Quick identification of target antigens by tissue flow cytometry for CAR-T therapy in B-cell malignancies.

Journal: Cytometry. Part B, Clinical cytometry

Published: September 09, 2021

Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL.

Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL.

Journal: Molecular therapy. Methods & clinical development

Published: May 20, 2021

CD19-specific CAR-T cell therapy for relapsed/refractory non-B-cell acute leukaemia with CD19 antigen expression.

CD19-specific CAR-T cell therapy for relapsed/refractory non-B-cell acute leukaemia with CD19 antigen expression.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 22, 2021

Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.

Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.

Journal: American journal of hematology

Published: December 31, 2020

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia.

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia.

Journal: Blood cancer journal

Published: September 15, 2019

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.

Journal: Leukemia

Published: January 30, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026